NVOS - Novo Integrated Sciences, Inc. Stock Price, Fair Value and News

0.48USD-0.02 (-4.00%)Market Closed

Market Summary

USD0.48-0.02

Market Closed

-4.00%

NVOS Stock Price

View Fullscreen

NVOS RSI Chart

NVOS Valuation

Market Cap

9.1M

Price/Earnings (Trailing)

-0.76

Price/Sales (Trailing)

0.67

EV/EBITDA

-0.9

Price/Free Cashflow

-1.85

NVOS Price/Sales (Trailing)

NVOS Profitability

Operating Margin

40.35%

EBT Margin

-88.55%

Return on Equity

-54.37%

Return on Assets

-34.52%

Free Cashflow Yield

-54.15%

NVOS Fundamentals

NVOS Revenue

Revenue (TTM)

13.7M

Rev. Growth (Yr)

24.02%

Rev. Growth (Qtr)

-18.52%

NVOS Earnings

Earnings (TTM)

-12.1M

Earnings Growth (Yr)

40.58%

Earnings Growth (Qtr)

41.08%

Breaking Down NVOS Revenue

Last 7 days

-17.2%

Last 30 days

-5.9%

Last 90 days

-34.2%

Trailing 12 Months

226.1%

How does NVOS drawdown profile look like?

NVOS Financial Health

Current Ratio

0.5

Debt/Equity

0.01

Debt/Cashflow

-16.1

NVOS Investor Care

Shares Dilution (1Y)

32.09%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	13.7M	0	0	0
2023	12.2M	12.4M	12.6M	13.0M
2022	8.9M	20.3M	11.7M	11.9M
2021	7.1M	8.5M	7.1M	8.1M
2020	9.9M	8.4M	7.9M	7.5M
2019	9.0M	9.2M	9.4M	9.7M
2018	8.7M	8.9M	8.9M	9.0M
2017	7.6M	7.8M	8.0M	8.4M
2016	0	0	7.2M	7.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Novo Integrated Sciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 20, 2022	oliva robert letterio	bought	11,156	2.2312	5,000	-
Apr 19, 2022	oliva robert letterio	bought	11,125	2.225	5,000	-
Apr 21, 2021	oliva robert letterio	bought	27,560	2.12	13,000	-
Feb 23, 2021	oliva robert letterio	bought	890	4.45	200	-
Feb 22, 2021	oliva robert letterio	bought	40,320	4.31	9,355	-

Which funds bought or sold NVOS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-13,245	-	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-11,109	16,214	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-2.00	2.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-74.05	-257	46.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	22.89	-2,002	5,385	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-2,000	4,000	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-95,777	-	-%
May 14, 2024	NORTHERN TRUST CORP	unchanged	-	-9,315	13,595	-%
May 13, 2024	XTX Topco Ltd	added	221	9,240	19,394	-%
May 13, 2024	UBS Group AG	sold off	-100	-9,945	-	-%

Are Funds Buying or Selling NVOS?

Are funds buying NVOS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NVOS

No. of Funds

Unveiling Novo Integrated Sciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	hudson bay capital management lp	0.08%	14,700	SC 13G/A
Feb 10, 2023	hudson bay capital management lp	9.99%	3,628,199	SC 13G/A
Feb 08, 2022	hudson bay capital management lp	9.99%	3,179,257	SC 13G
Feb 08, 2022	hudson bay capital management lp	9.99%	3,179,257	SC 13G

Recent SEC filings of Novo Integrated Sciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	8-K	Current Report
Apr 15, 2024	10-Q	Quarterly Report
Apr 11, 2024	8-K	Current Report
Apr 10, 2024	8-K	Current Report
Mar 26, 2024	8-K	Current Report
Mar 19, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report
Feb 21, 2024	8-K	Current Report
Feb 20, 2024	8-K	Current Report
Feb 16, 2024	8-K	Current Report

Peers (Alternatives to Novo Integrated Sciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	482.9B	379.5B	9.53%	9.48%	31.44	1.27	12.96%	-25.81%
CI	96.2B	206.0B	-2.11%	32.08%	24.97	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	3.80%	15.55%	15.46	1.27	9.59%	-4.59%
CVS	72.4B	360.9B	-15.92%	-16.78%	9.89	0.2	9.07%	78.49%
CNC	41.7B	155.5B	8.44%	18.66%	15.24	0.27	6.34%	84.42%
DVA	12.3B	12.3B	9.53%	38.52%	15.03	0.99	5.77%	58.74%
UHS	11.9B	14.7B	11.04%	30.82%	14.63	0.81	7.99%	19.23%
MID-CAP
CHE	8.5B	2.3B	-6.47%	5.37%	30.15	3.73	5.96%	18.29%
ACHC	6.2B	3.0B	-5.49%	-7.73%	-545.12	2.06	10.92%	-104.06%
AMEH	2.3B	1.5B	9.06%	20.53%	36.62	1.57	19.34%	40.15%
AMN	2.2B	3.5B	4.01%	-38.44%	15.49	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	14.53%	25.72%	27.59	1.67	11.45%	30.74%
BKD	1.3B	3.0B	6.97%	85.25%	-7.66	0.44	4.98%	4.88%
BEAT	54.5M	-	-4.17%	-6.33%	-3.61	-	-	-1.05%
AMS	22.0M	21.6M	16.05%	23.93%	39.79	1.02	9.04%	-50.63%

Novo Integrated Sciences, Inc. News

Latest updates

Novo Integrated Sciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-18.5%	3,170,592	3,891,218	3,303,297	3,292,933	2,556,509	3,419,280	8,635,582	13,851,883	2,869,223	3,161,927	446,390	2,380,974	2,075,894	2,155,506	1,844,867	1,038,226	2,428,864	2,548,610	2,420,218	2,489,575	2,200,410
Cost Of Revenue	-5.2%	1,846,506	1,947,200	2,375,112	1,978,839	1,585,606	1,679,747	-8,052,632	11,443,001	1,652,869	1,895,461	1,713,237	1,100,516	1,324,448	1,344,056	1,023,418	559,976	1,585,860	1,632,941	1,596,693	1,556,865	1,320,740
Gross Profit	-31.9%	1,324,086	1,944,018	928,185	1,314,094	970,903	1,739,533	-92,464	2,408,882	1,216,354	1,266,466	979,644	1,280,458	751,446	811,450	821,449	478,250	843,004	915,669	823,525	932,710	879,670
Operating Expenses	-45.6%	2,863,854	5,261,655	4,022,159	2,744,512	2,757,713	3,981,493	20,247,132	3,611,628	3,337,030	2,630,125	2,867,523	1,682,430	2,077,390	1,569,174	4,777,903	556,801	993,772	992,494	1,251,955	995,838	958,357
S&GA Expenses	-73.0%	2,590	9,586	5,233	1,877	707	7,332	-15,638	9,802	26,370	168	3,299	2,381	602	1,243	426	2,389	884	1,222	6,846	3,846	4,016
EBITDA Margin	20.7%	-0.69	-0.87	-0.84	-2.32	-2.52	-2.57	-2.43	-0.39	-0.58	-0.40	-0.37	-0.50	-0.60	-	-	-	-	-	-	-	-
Interest Expenses	206.0%	138,684	45,321	88,216	67,888	123,866	186,911	207,907	-	1,230,390	64,522	96,250	21,701	22,948	19,642	-31,072	48,245	37,717	40,329	117,712	35,154	34,509
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	41.1%	-2,745,560	-4,660,723	-3,202,251	-1,485,295	-4,645,162	-3,936,736	-22,638,856	-3,744,025	-4,868,204	-1,816,395	-1,941,970	-415,271	-1,340,591	-773,103	-4,228,398	-101,023	-505,829	-88,959	76,758	-100,773	-122,980
EBT Margin	17.5%	-0.89	-1.07	-1.06	-2.65	-2.88	-2.95	-2.82	-0.61	-1.02	-0.68	-0.63	-0.80	-0.91	-	-	-	-	-	-	-	-
Net Income	41.1%	-2,746,128	-4,660,723	-3,159,792	-1,497,330	-4,621,355	-3,936,736	-22,390,984	-3,810,054	-4,868,204	-1,816,395	549,666	-411,187	-1,340,591	-773,103	-4,014,728	-98,295	-505,829	-88,959	82,515	-99,258	-122,980
Net Income Margin	17.3%	-0.88	-1.07	-1.05	-2.63	-2.86	-2.93	-2.80	-0.49	-0.74	-0.37	-0.28	-0.77	-0.88	-	-	-	-	-	-	-	-
Free Cashflow	20.4%	-1,713,595	-2,152,358	-259,126	-856,917	-877,779	-277,432	676,567	-3,548,612	-2,322,768	-879,500	-800,102	-50,259	-282,287	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-6.2%	34,949	37,244	35,563	35,745	36,489	37,749	40,873	71,793	70,320	63,934	61,958	42,228	34,857	34,836	35,391	36,572	36,640	32,104	32,273	31,682	29,081
Current Assets	-26.3%	5,019	6,809	4,388	3,998	4,051	4,457	5,732	20,079	19,015	12,243	11,134	10,832	3,605	4,155	4,295	3,929	4,114	4,168	4,099	4,588	4,503
Cash Equivalents	-60.3%	652	1,640	416	464	610	879	2,179	12,677	15,944	8,801	8,293	8,367	1,698	1,970	2,068	1,394	1,209	1,932	2,084	2,478	2,374
Inventory	-25.5%	947	1,271	1,107	939	925	1,010	879	645	334	364	339	-	-	-	-	-	-	-	-	-	-
Net PPE	-1.1%	5,246	5,307	5,390	5,411	5,449	5,564	5,801	5,932	6,158	6,097	6,070	550	318	333	354	347	368	392	410	418	427
Goodwill	0.1%	7,561	7,555	7,582	7,543	7,539	7,596	7,826	11,367	9,059	8,956	9,489	688	652	640	637	603	619	625	623	584	600
Liabilities	-6.5%	13,059	13,960	11,064	9,454	9,526	17,064	18,825	27,365	25,805	20,266	18,154	5,617	5,722	5,687	5,819	5,974	6,340	6,531	6,729	6,368	4,252
Current Liabilities	-8.8%	9,959	10,916	7,905	6,209	6,178	12,565	14,075	12,730	11,554	15,653	8,464	3,524	3,658	2,595	2,600	2,530	2,662	2,948	3,028	4,579	3,037
Shareholder's Equity	-4.7%	22,189	23,284	24,816	26,567	26,963	20,685	22,048	44,428	44,515	43,668	43,804	36,610	29,135	29,149	29,572	30,599	30,300	25,574	25,544	25,313	24,829
Retained Earnings	-3.8%	-74,459	-71,713	-67,033	-63,872	-62,375	-57,753	-53,818	-31,391	-27,581	-22,775	-20,969	-19,029	-18,618	-17,278	-16,507	-12,282	-12,184	-11,680	-11,591	-11,670	-11,570
Additional Paid-In Capital	0.6%	96,083	95,481	90,973	89,250	88,321	69,135	66,085	64,621	60,692	55,092	54,579	54,298	46,155	45,033	44,905	41,614	41,166	35,926	35,813	35,695	35,048
Accumulated Depreciation	-	1,378	-	1,253	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	2.6%	17,748	17,291	15,759	14,486	7,933	3,386	3,118	2,850	2,874	2,692	2,661	2,419	2,363	-	-	-	-	-	-	-	-
Minority Interest	0.3%	-298	-299	-316	-275	-287	-262	-257	55.00	-36.29	26.00	-60.26	-60.63	-53.40	-51.72	-49.86	-43.14	-41.51	-40.59	-39.63	-37.65	-37.10
Float	-	-	-	-	-	16,083	-	-	-	14,672	-	-	-	28,576	-	-	-	17,071	-	-	-	67,113

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	20.4%	-1,713	-2,152	-228	-857	-878	-278	676	-3,550	-2,250	-759	-745	150	-281	-148	-15.56	153	-281	-297	-291	-71.43	-296
Cashflow From Investing	-	-	-	-30.35	-	-	-	805*	326	-72.14	-91.11	3,681	-680	-	-	925	-2.70	-379	114	-136	-404	-227
Cashflow From Financing	-99.9%	3.00	3,296	468	901	429	-1,034	-11,229	-37.24	9,440	1,400	-2,845	7,141	-22.33	44.00	-315	71.00	-57.11	30.00	-3.13	639	1,940

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NVOS Income Statement

2024-02-29

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Income Statement [Abstract]
Revenues	$ 3,170,592	$ 2,556,509	$ 7,061,810	$ 5,975,789
Cost of revenues	1,846,506	1,585,606	3,793,706	3,265,353
Gross profit	1,324,086	970,903	3,268,104	2,710,436
Operating expenses:
Selling expenses	2,590	707	12,176	8,039
General and administrative expenses	2,861,264	2,757,006	8,113,333	6,731,167
Total operating expenses	2,863,854	2,757,713	8,125,509	6,739,206
Loss from operations	(1,539,768)	(1,786,810)	(4,857,405)	(4,028,770)
Non-operating income (expense)
Interest income	2,477	2,243	4,696	4,524
Interest expense	(138,684)	(123,866)	(282,058)	(291,109)
Other expense	(308,763)		(960,937)
Change in fair value of derivative liability	373,339		958,868
Amortization of debt discount	(1,114,573)	(2,740,349)	(2,190,501)	(4,230,862)
Foreign currency transaction (loss) gain	(19,588)	3,620	(78,946)	(35,681)
Total other expense	(1,205,792)	(2,858,352)	(2,548,878)	(4,553,128)
Loss before income taxes	(2,745,560)	(4,645,162)	(7,406,283)	(8,581,898)
Income tax expense
Net loss	(2,745,560)	(4,645,162)	(7,406,283)	(8,581,898)
Net income (loss) attributed to noncontrolling interest	568	(23,807)	20,188	(25,130)
Net loss attributed to Novo Integrated Sciences, Inc.	(2,746,128)	(4,621,355)	(7,426,471)	(8,556,768)
Comprehensive loss:
Foreign currency translation gain (loss)	750,067	(196,683)	860,764	(617,665)
Comprehensive loss:	$ (1,995,493)	$ (4,841,845)	$ (6,545,519)	$ (9,199,563)
Weighted average common shares outstanding - basic	17,642,829	7,933,492	17,184,569	5,646,937
Weighted average common shares outstanding - diluted	17,642,829	7,933,492	17,184,569	5,646,937
Net loss per common share - basic	$ (0.16)	$ (0.59)	$ (0.43)	$ (1.52)
Net loss per common share - diluted	$ (0.16)	$ (0.59)	$ (0.43)	$ (1.52)

NVOS Balance Sheet

2024-02-29

Condensed Consolidated Balance Sheets - USD ($)	Feb. 29, 2024	Aug. 31, 2023
Current Assets:
Cash and cash equivalents	$ 651,747	$ 416,323
Accounts receivable, net	2,153,914	1,467,028
Inventory, net	947,351	1,106,983
Other receivables	1,048,596	1,051,584
Prepaid expenses and other current assets	217,619	346,171
Total current assets	5,019,227	4,388,089
Property and equipment, net	5,246,241	5,390,038
Intangible assets, net	15,205,967	16,218,539
Right-of-use assets, net	1,916,900	1,983,898
Goodwill	7,560,936	7,582,483
TOTAL ASSETS	34,949,271	35,563,047
Current Liabilities:
Accounts payable	2,173,667	3,513,842
Accrued expenses	1,328,828	1,233,549
Accrued interest (including amounts to related parties)	477,480	382,666
Government loans and notes payable, current portion	93,488	277,405
Convertible notes payable, net of discount of $2,004,245	1,773,533	558,668
Derivative liability	2,312,921
Contingent liability	27,756	61,767
Debentures, related parties	914,219	916,824
Finance lease liability	5,788	11,744
Operating lease liability, current portion	417,342	415,392
Total current liabilities	9,959,061	7,904,858
Government loans and notes payable, net of current portion	64,016	65,038
Operating lease liability, net of current portion	1,639,391	1,693,577
Deferred tax liability	1,396,519	1,400,499
TOTAL LIABILITIES	13,058,987	11,063,972
Commitments and contingencies
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at February 29, 2024 and August 31, 2023, respectively
Common stock; $0.001 par value; 499,000,000 shares authorized; 17,748,320 and 15,759,325 shares issued and outstanding at February 29, 2024 and August 31, 2023, respectively	17,749	15,760
Additional paid-in capital	96,082,626	90,973,316
Common stock to be issued (17,375 and 91,138 shares at February 29, 2024 and August 31, 2023)	44,443	1,217,293
Other comprehensive gain (loss)	503,381	(357,383)
Accumulated deficit	(74,459,512)	(67,033,041)
Total Novo Integrated Sciences, Inc. stockholders’ equity	22,188,687	24,815,945
Noncontrolling interest	(298,403)	(316,870)
Total stockholders’ equity	21,890,284	24,499,075
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	34,949,271	35,563,047
Related Party [Member]
Current Liabilities:
Due to related parties	$ 434,039	$ 533,001

About Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary health care related products and services. It operates through two segments, Healthcare Services and Product Sales. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services. It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics, including pediatric, adult, and geriatric populations. In addition, the company offers eldercare physiotherapy services, such as long-term care homes, retirement homes, community-based home care physiotherapy, community-based group exercise classes and fall prevention programs, and community-based outpatient clinics; and elderly occupational therapy services for retirement home and community, and long-term care sectors. Further, it offers medical technology services, such as telemedicine and remote patient monitoring; and develops and distributes personalized health and wellness product solutions. The company operates corporate-owned clinics. The company is based in Bellevue, Washington. Novo Integrated Sciences, Inc. is a subsidiary of ALMC-ASAP Holdings, Inc.

CEO	Mr. Robert Mattacchione
WEBSITE	novointegrated.com
INDUSTRY	Healthcare Plans
EMPLOYEES	115

Novo Integrated Sciences, Inc. Frequently Asked Questions

What is the ticker symbol for Novo Integrated Sciences, Inc.? What does NVOS stand for in stocks?

NVOS is the stock ticker symbol of Novo Integrated Sciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Novo Integrated Sciences, Inc. (NVOS)?

As of Fri May 17 2024, market cap of Novo Integrated Sciences, Inc. is 9.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVOS stock?

You can check NVOS's fair value in chart for subscribers.

What is the fair value of NVOS stock?

You can check NVOS's fair value in chart for subscribers. The fair value of Novo Integrated Sciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Novo Integrated Sciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NVOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Novo Integrated Sciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether NVOS is over valued or under valued. Whether Novo Integrated Sciences, Inc. is cheap or expensive depends on the assumptions which impact Novo Integrated Sciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVOS.

What is Novo Integrated Sciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NVOS's PE ratio (Price to Earnings) is -0.76 and Price to Sales (PS) ratio is 0.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVOS PE ratio will change depending on the future growth rate expectations of investors.